Henry Schein (HSIC) : Duncker Streett Co Inc reduced its stake in Henry Schein by 2.24% during the most recent quarter end. The investment management company now holds a total of 20,625 shares of Henry Schein which is valued at $3,726,113 after selling 472 shares in Henry Schein , the firm said in a disclosure report filed with the SEC on Jul 20, 2016.Henry Schein makes up approximately 1.29% of Duncker Streett Co Inc’s portfolio.
Other Hedge Funds, Including , Montrusco Bolton Investments reduced its stake in HSIC by selling 6,038 shares or 21.1% in the most recent quarter. The Hedge Fund company now holds 22,573 shares of HSIC which is valued at $4,078,038. Henry Schein makes up approx 0.25% of Montrusco Bolton Investments’s portfolio.Fisher Asset Management reduced its stake in HSIC by selling 2,719 shares or 0.54% in the most recent quarter. The Hedge Fund company now holds 496,793 shares of HSIC which is valued at $89,974,180. Henry Schein makes up approx 0.17% of Fisher Asset Management’s portfolio.Chevy Chase Trust Holdings boosted its stake in HSIC in the latest quarter, The investment management firm added 8,624 additional shares and now holds a total of 223,907 shares of Henry Schein which is valued at $40,464,473. Henry Schein makes up approx 0.22% of Chevy Chase Trust Holdings’s portfolio.Kistler-tiffany Companies reduced its stake in HSIC by selling 100 shares or 20.0% in the most recent quarter. The Hedge Fund company now holds 400 shares of HSIC which is valued at $72,288. Henry Schein makes up approx 0.04% of Kistler-tiffany Companies’s portfolio.
Henry Schein opened for trading at $180.62 and hit $181.44 on the upside on Wednesday, eventually ending the session at $180.86, with a gain of 0.19% or 0.35 points. The heightened volatility saw the trading volume jump to 2,07,206 shares. Company has a market cap of $14,843 M.
On the company’s financial health, Henry Schein reported $1.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $1.39. The company had revenue of $2712.96 million for the quarter, compared to analysts expectations of $2667.28 million. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.
Many Wall Street Analysts have commented on Henry Schein. Company shares were Reiterated by Barrington Research on May 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 188 from a previous price target of $182 .
Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.